Navigation Links
Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
Date:5/23/2012

Also, as recently announced, Insmed has begun dosing patients in CLEAR-108, a European and Canadian registrational phase 3 clinical study of ARIKACE in CF patients with Pseudomonas aeruginosa lung infections, and is proceeding with CLEAR-110, a follow-on multi-cycle open-label study intended primarily to measure safety and tolerability for patients who complete CLEAR-108. 

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases.  Insmed's primary focus is on the development of inhaled antibiotic therapy delivered via proprietary advanced liposomal pulmonary technology in areas of high unmet need.  For more information, please visit http://www.insmed.com.

About eFlow® Technology and PARI Pharma

ARIKACE is delivered by an investigational eFlow® Nebulizer System developed by PARI Pharma and optimized specifically for ARIKACE. The optimized device uses eFlow Technology to enable highly efficient aerosolization of medication including liposomal formulations via a vibrating, perforated membrane that includes thousands of laser drilled holes. Compared to other nebulization technologies, eFlow Technology produces aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible period of time. eFlow Technology is not an ultrasonic nebulizer technology, and it is not a general purpose electronic aerosol generator nebulizer technology. Combined with its quiet mode of operation, small size, light weight, and battery use, eFlow Technology reduces the burden of taking daily, inhaled treatments. PARI Pharma focuses on the development of aerosol delivery devices and inhalation drug development to advance aerosol therapies where drug and d
'/>"/>

SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Insmed Announces First Quarter 2012 Financial Results
2. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
3. Insmed to Host 2012 First Quarter Earnings Conference Call
4. Insmed to Host Fourth Quarter and 2011 Year-End Earnings Conference Call
5. Insmed to Present at Lazard Capital Markets 8th Annual Healthcare Conference
6. Insmed Incorporated Provides Regulatory Update on ARIKACE® in Non-Tuberculous Mycobacteria Indication
7. Insmed Incorporated Provides Regulatory Update
8. Insmed to Present at Sixth Annual JMP Securities Healthcare Conference
9. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011
10. Insmeds ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections
11. Insmed Announces First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015  Oncobiologics, Inc., a biotherapeutics company ... biosimilars, has completed the construction of its GMP ... Cranbury, New Jersey . ... is designed to utilize multiple technologies that enable ... Through the use of the latest single-use technologies, ...
(Date:5/4/2015)... May 4, 2015   HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of advanced ... Godshall , is scheduled to present at the Bank of ... Las Vegas on Thursday, May 14, 2015, at ... webcast of the Company,s presentation at the conference will be ...
(Date:5/4/2015)... May 4, 2015  CytRx Corporation (Nasdaq: ... specializing in oncology, today announced an interim analysis ... studies pairing aldoxorubicin with either gemcitabine or ifosfamide. ... ifosfamide with escalating doses of aldoxorubicin. The combinations ... the lowest dose level of aldoxorubicin (170 mg/m2), ...
Breaking Medicine Technology:Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7
... SUNNYVALE, Calif., Dec. 22 Arrayit Corporation (OTC Bulletin Board: ... that the Company has made a technological breakthrough in the ... which are tiny glass substrates that contain rows and columns ... The advance allows highly precise printing of as many as ...
... , NEW YORK, Dec. 22 Delcath Systems, Inc. (Nasdaq: ... treatment method for primary and metastatic cancers to the liver, ... Scientific Advisory Board, effective immediately. , "We formed our ... our Delcath PHP System(TM) with insight from the leading experts ...
Cached Medicine Technology:Arrayit Corporation Announces Manufacturing Breakthrough 2Arrayit Corporation Announces Manufacturing Breakthrough 3Professor Riccardo Lencioni Joins Delcath Systems' Scientific Advisory Board 2Professor Riccardo Lencioni Joins Delcath Systems' Scientific Advisory Board 3
(Date:5/4/2015)... 04, 2015 Leonardo J. Lozada, M.D., ... physician executive, and William C. Daniel, M.D., Saint Luke’s ... personal invitations from the Secretary of the Air Force ... at the Air War College, Maxwell Air Force Base, ... citizens to senior U.S. and international officers and their ...
(Date:5/4/2015)... Pa. (PRWEB) May 04, 2015 Milton ... ’87, the 2015 Alumnus of the Year, recognizing his ... excellence and philanthropy he sets for MHS students. , ... that can happen when children are provided a top-notch ... and hone their passions,” said Pete Gurt ’85, president ...
(Date:5/4/2015)... York, NY (PRWEB) May 04, 2015 ... specialized insurance programs, announces the expansion of coverage for ... is a leading provider of industry-tailored insurance and proactive ... McNeil & Company, we are dedicated to providing our ... to meet their many evolving needs. We are excited ...
(Date:5/4/2015)... “ LiveSchool ” was featured on ... a look at the latest and coolest applications on ... the host of AppWatch and technology expert, conducted the ... allows teachers to reward students with good behavior. , ... in the classroom. And the good people at ...
(Date:5/4/2015)... May 04, 2015 The American Telemedicine ... state policy reports which identify gaps in coverage and ... ATA issued the State Telemedicine Gaps Reports last September, ... their laws and regulations impact healthcare delivery in their ... result of state actions across the nation, ATA reevaluated ...
Breaking Medicine News(10 mins):Health News:Saint Luke’s Health System Leadership Selected to Attend National Security Forum 2Health News:Milton Hershey School Names 2015 Alumnus of the Year 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 3
... year saga of HIV Positive patient Shenequa Flucas is an ... hold the key to curb its escalation. // ,She ... second baby. Depressed with low self esteem, she is ... she received, that opened her mind rather than closing it. ...
... of beauty are most commonly blamed for lowering self-esteem ... trend, // a lot of marketing companies (including Dove) ... messages in an effective way. ,A new ... more likely to lower the onlooker’s self esteem, contrary ...
... study has highlighted that women exposed to high levels of ... than those who have a smooth sail through life. The ... that evaluated the stress levels of women between 1994 and ... were more likely to die over the next 8 years. ...
... Drugs meant for treatment of Attention Deficit Hyperactivity Disorder ... be subjected to stringent clinical trials to assess the ... ,The decision has been taken following the reports ... warnings should be associated with marketing of such drugs. ...
... of fluid filled plastic teething ring, manufactured by The ... been urged by the Food and Drug Administration to ... ,The contaminated liquid if swallowed or absorbed through ... sickness. Malnourished infants, infants with compromised immune function or ...
... (NY) and Catholic University of America in Washington, D.C. ... between themselves affects the emotional development of the// children. ... the psyche of their children is detailed in the ... ,"A useful analogy is to think about emotional security ...
Cached Medicine News:Health News:Parental Conflicts Lead To Emotional Insecurity In Children 2
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes....
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
The AMY method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of amylase activity in serum, plasma and urine....
Enzymatic Clearance assay for the in vitro quantitative determination of LDL-cholesterol in human serum and plasma....
Medicine Products: